【摘要】 目的观察LHRH-PE40对各种病理型宫颈癌组织的结合能力,为其临床应用提供理论依据。方法采用免疫荧光法检测LHRH-PE40与正常宫颈组织及宫颈癌组织的结合能力。结果宫颈结缔组织、鳞状上皮的荧光结合率为0%。宫颈癌组织荧光结合率为74%,弱阳性及阴性表达病例中,高分化鳞状细胞癌占67%,中低分化鳞状细胞癌占15%,两者差异有显著意义(P<0.05)。中强阳性表达病例中,高分化鳞状细胞癌仅占37%,中低分化鳞状细胞癌占86%,两者差异有显著意义(P<0.05)。5例强阳性表达病例均为高分化腺癌。结论高分化鳞状细胞癌与LHRH-PE40结合能力最弱,子宫颈腺癌与LHRH-PE40结合能力最强。更多还原

【Abstract】 Objective To observe the binding capacity of LHRH-PE40 to cervical carcinoma tissues of various physiological types and provide theoretical basis for the clinical application of LHRH-PE40.Methods Determine the binding capacity of LHRH-PE40 to cervical carcinoma tissue by IFA.Results The binding capacities of LHRH-PE40 to cervical connective tissue and squamous epithelium were 0%,and that to cervical carcinoma tissue was 74%.Of weak IFA-positive and IFA-negative specimens,67% were high differential squamous cell carcinoma tissues,and 15% were low differential squamous cell carcinoma tissues(P<0.05).However,of moderate IFA-positive specimens,37% were high differential squamous cell carcinoma tissues,and 85% were moderate and low differential squamous cell carcinoma tissues(P<0.05).All the three strong IFA-positive specimens were high differential adenocarcinoma tissues.Conclusion LHRH-PE40 showed the lowest binding capacity to high differential squamous cell carcinoma tissue and the highest binding capacity to cervical carcinoma tissue.The binding capacity of LHRH-PE40 to moderate and low differential squamous cell carcinoma tissues was 86%.更多还原